Ryan Grange
Medical · Edgewood, NMNPI 1295194629
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 93 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 17.3% — the pattern of someone who eats at a lot of different presentations.
Across 93 payments — averaging $18.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$295
- Amgen$265
- Aimmune Therapeutics, Inc.$192
- Pfizer$152
- GSK$130
- AstraZeneca$122
- plus $545 from 16 others
What the payments were for
- Food & beverage$1,702100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 14 | $295 |
| Amgen | 15 | $265 |
| Aimmune Therapeutics, Inc. | 11 | $192 |
| Pfizer | 7 | $152 |
| GSK | 8 | $130 |
| AstraZeneca | 7 | $122 |
| Novo Nordisk | 6 | $95 |
| Exact Sciences | 4 | $62 |
| Bayer | 3 | $57 |
| Otsuka America Pharmaceutical, Inc. | 3 | $46 |
| AbbVie | 2 | $38 |
| Phathom Pharmaceuticals, Inc. | 2 | $36 |
| Astellas Pharma US Inc | 1 | $35 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Novartis | 1 | $25 |
| Viatris Specialty LLC | 1 | $22 |
| SK Life Science, Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $19 |
| Boehringer Ingelheim | 1 | $17 |
| Merck | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Baxter Healthcare | 1 | $14 |
How this compares
$1,702 in reported general payments places this provider in the 80th percentile of 156 medical providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 46 | $50,860 |
| XareltoRivaroxaban | 20 | $24,160 |
| FarxigaDapagliflozin Propanediol | 22 | $22,129 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $20,234 |
| TrulicityDulaglutide | 19 | $19,886 |
| EliquisApixaban | 15 | $19,514 |
| MounjaroTirzepatide | 14 | $15,663 |
| Spiriva RespimatTiotropium Bromide | 25 | $13,169 |
| SymbicortBudesonide/Formoterol Fumarate | 27 | $8,768 |
| Atorvastatin Calcium | 371 | $6,101 |
| Levothyroxine Sodium | 293 | $4,101 |
| Fluticasone Propionate HfaFluticasone Propionate | 23 | $3,775 |
| Losartan Potassium | 209 | $3,528 |
| Arnuity ElliptaFluticasone Furoate | 13 | $3,516 |
| Gabapentin | 259 | $3,511 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $95 | $50,86046 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $295 | $35,54933 claims |
| AstraZenecaFarxiga, Symbicort | $122 | $30,89849 claims |
| Johnson & JohnsonXarelto | $19 | $24,16020 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta | $130 | $23,75033 claims |
| PfizerEliquis | $152 | $19,51415 claims |
| Boehringer IngelheimSpiriva Respimat | $17 | $13,16925 claims |
| AbbVieSynthroid | $38 | $1,26015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 156 medical providers in New Mexico.
Other medical in Edgewood
- Brenda PachecoAcoma$12K
- Paul TapiaAlbuquerque$7K
- Niki NinopoulosAlbuquerque$7K
- William BaconSanta Fe$6K
- Katie JoshiAlbuquerque$6K
- Loretta GonzalesAlbuquerque$5K
- Sarah East BrumanaRoswell$5K
- Ruben FrancoAlbuquerque$4K
- Bradford GwytherAlbuquerque$4K
- Danny MaysSanta Fe$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.